NIH grant program investigates COVID-19's impact on underserved and vulnerable populations
The National Institutes of Health is offering several grants to increase research into the growing body of evidence suggesting that underserved and/or vulnerable populations are more susceptible to COVID-19 infection, severe complications and associated death, as well as to the pandemic's social, behavioral and economic impacts. Through NIH's National Institute on Minority Health and Health Disparities, the following grant opportunities are being made available:
- Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
- Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
- RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)
- Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…